Boundless Bio (BOLD)

• Market cap: $36.1M
• 1 day: -4.71%
• 5 days: -3.57%
• 1 month: -27.68%
• 3 months: -34.15%
• 6 months: -54.87%
• Year to date: -40.66%
• 1 year: -88.63%
• 5 years: -88.63%
• 10 years: -88.63%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Employees: 72

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

600% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 4

13% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 8

2% more funds holding

Funds holding: 54 [Q3] → 55 (+1) [Q4]

0.85% less ownership

Funds ownership: 58.98% [Q3] → 58.13% (-0.85%) [Q4]

17% less capital invested

Capital invested by funds: $45.6M [Q3] → $37.6M (-$7.96M) [Q4]